Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Victor Rodriguez Laval"'
Autor:
Carmen Maria Perez Fernandez, Uli Fehrenbach, Marianne Pavel, Victor Rodriguez-Laval, Henning Jann, Timm Denecke
Background Everolimus, a mammalian target of rapamycin (mTOR)-inhibitor, is approved for the treatment of advanced neuroendocrine neoplasms (NEN). A rare major adverse event is the occurrence of drug-induced pneumonitis. Purpose To evaluate the corre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5f2b4dba155a9df16266b3018cdeb55
https://opus4.kobv.de/opus4-fau/files/17896/10.1177_0284185120950100.pdf
https://opus4.kobv.de/opus4-fau/files/17896/10.1177_0284185120950100.pdf
Autor:
Johannes Meiler, Victor Rodriguez-Laval, Steffen Heeg, Anja A. Kühl, Ruza Arsenic, Ulrich-Frank Pape, Karel Caca, Stefan Kasper, Holger Jansen, Arndt Vogel, Oswald Burkhard, Petra Büchner-Steudel, Marianne Sinn, Peter Treasure, Nalân Utku, Lothar Müller
Publikováno v:
Cancers
Volume 12
Issue 11
Cancers, Vol 12, Iss 3149, p 3149 (2020)
Volume 12
Issue 11
Cancers, Vol 12, Iss 3149, p 3149 (2020)
CAP7.1 is a novel topoisomerase II inhibitor, converted to active etoposide via carboxylesterase 2 (CES2), with signals of efficacy in treatment-refractory solid tumours. In a Phase II trial, 27 patients with advanced biliary tract cancers (BTC) were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0afa236a2b6ccc2afac733832775c664
Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome
Autor:
Victor Rodriguez-Laval, Anja Rinke, Rainer W. Lipp, Elettra Merola, Maria Rinzivillo, Francesco Panzuto, Marianne Pavel, Stefano Partelli, Ulrich Frank Pape, Massimo Falconi, Bertram Wiedenmann, Gianfranco Delle Fave, Thomas M. Gress, Patrizia Kump
Publikováno v:
The Oncologist. 22:409-415
Background Several risk factors predict clinical outcome in gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs); however, the impact of their combination has not been investigated so far. Patients and Methods A retrospective analysis of stag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a32bf0652b9afcbac9990f0cb0b8cf29
https://doi.org/10.1634/theoncologist.2016-0351
https://doi.org/10.1634/theoncologist.2016-0351
Autor:
Ulrich-Frank Pape, Oswald Burkhard, Nalan Utku, Karel Caca, Steffen Heeg, Ruza Arsenic, Lothar Mueller, Marianne Sinn, Anya A Kühl, Johannes Meiler, Holger Jansen, Arndt Vogel, Victor Rodriguez Laval, Stefan Kasper
264 Background: The novel drug EDO-S7.1 (CAP7.1) is converted to active etoposide by CES allowing administration of higher doses, reducing resistance, and permitting treatment of advanced tumors. Methods: The primary objective was to compare disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9884cad576c01a7ea15c3ebf4032cc29
Autor:
Karel Caca, Glyn B. Steventon, Ulrich Frank Pape, Marianne Sinn, Jan Kuhlmann, Stefan Kasper, Lothar Mueller, Johannes Meiler, Matthias Machacek, Arndt Vogel, Ulrich Keilholz, Holger Jansen, Oswald Burkhard, Victor Rodriguez Laval, Nalan Utku
Publikováno v:
Journal of Clinical Oncology. 34:e15602-e15602
e15602Background: The aim of this study was to describe the population pharmacokinietics (PK) of CAP7.1, the prodrug of etoposide, and to describe how changes in total target lesion (TTL) size in b...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf691b33ef23214e279bb72bd8d8dbb3
https://doi.org/10.1200/jco.2016.34.15_suppl.e15602
https://doi.org/10.1200/jco.2016.34.15_suppl.e15602